Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TYK2 inhibitor

- PMLiVE

EU approval for Takeda’s schizophrenia drug

Latuda said to have improved side effect profile compared to other treatments

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Takeda promotes Giles Platford

Appoints him head of commercial operations, emerging markets

- PMLiVE

Takeda CEO admits to Blopress mis-marketing

Campaign used graph indicating drug was superior to Pfizer’s Norvasc

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

- PMLiVE

Takeda pipeline hit by fasiglifam failure

Diabetes candidate had been set for a 2015 launch

- PMLiVE

FDA panel backs Takeda’s inflammatory bowel disease drug

Vedolizumab on course for US approval to treat Crohn’s disease and ulcerative colitis

- PMLiVE

Takeda appoints GSK’s Weber as chief operating officer

Could take on CEO role next year

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

Research Partnership

- PMLiVE

Celgene lifted by apremilast data in psoriatic arthritis

Long-term data keeps marketing application plans on course

- PMLiVE

New US drug discovery institute partners with Takeda

Tri-Institutional Therapeutics Discovery Institute to cover communicable, chronic and rare conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links